The new shares have equally been subscribed by the major investors of the company, Santo Holding – the family office of the Strüngmann family – as well as the MIG Funds advised by MIG Verwaltungs AG and the new investor FCPG Affi GmbH.
The company focuses on the development, both preclinical and clinical, of vaccines in hypercholesterolemia and atherosclerosis prevention and expects data from this study in Q1 2017.
AFFiRiS has been able to attract funding of approx. EUR 130m to date, half of which comes from license income and government grants. AFFiRiS currently employs 60 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria.